Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome

Rui-Lin Ma, Yan Deng, Yan-Fang Wang, Shi-Yang Zhu, Xue-Song Ding, Ai-Jun Sun, Rui-Lin Ma, Yan Deng, Yan-Fang Wang, Shi-Yang Zhu, Xue-Song Ding, Ai-Jun Sun

Abstract

Background: Obesity and insulin resistance (IR) are common features of polycystic ovary syndrome (PCOS). Metformin (MET) increases insulin sensitivity, but it is associated with unsatisfactory weight loss. The glucagon-like peptide-1 receptor agonist exenatide has been shown to reduce weight and IR in patients with diabetes. This study aimed to explore the therapeutic effects of exenatide once-weekly (QW) combined with MET on body weight, as well as metabolic and endocrinological parameters in overweight/obese women with PCOS.

Methods: Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks. The primary outcomes were anthropometric changes associated with obesity, and the secondary outcomes included changes in reproductive hormone levels, glucose and lipid metabolism, and C-reactive protein.

Results: Forty (80%) patients completed the study. COM therapy was superior to MET monotherapy in reducing weight (P = 0.045), body mass index (BMI) (P = 0.041), and waist circumference (P = 0.023). Patients in the COM group on an average lost 3.8 ± 2.4 kg compared with 2.1 ± 3.0 kg in the MET group. In the COM group, BMI and waist circumference decreased by 1.4 ± 0.87 kg/m2 and 4.63 ± 4.42 cm compared with 0.77 ± 1.17 kg/m2 and 1.72 ± 3.07 cm in the MET group, respectively. Moreover, levels of fasting glucose, oral glucose tolerance test (OGTT) 2-h glucose, and OGTT 2-h insulin were significantly lower with COM therapy than with MET (P < 0.050). Mild and moderate gastrointestinal reactions were the most common adverse events in both groups.

Conclusions: COM therapy was more effective than MET alone in reducing body weight, BMI, and waist circumference, and improving insulin sensitivity in overweight/obese women with PCOS, with acceptable short-term side effects.

Trial registration: ClinicalTrials.gov, NCT04029272. https://ichgcp.net/clinical-trials-registry/NCT04029272.

Conflict of interest statement

None.

Copyright © 2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

Figures

Figure 1
Figure 1
Study flow chart. COVID-19: Coronavirus disease 2019; QW: Once-weekly; bid: Twice a day; tid: Three times a day; qd: One a day.

References

    1. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018; 14:270–284. doi: 10.1038/nrendo.2018.24.
    1. Barber TM, Hanson P, Weickert MO, Franks S. Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health 2019; 13:1179558119874042.doi: 10.1177/1179558119874042.
    1. Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ, et al. . Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2019; 3:CD007506.doi: 10.1002/14651858.CD007506.pub4.
    1. Marzouk TM, Sayed Ahmed WA. Effect of dietary weight loss on menstrual regularity in obese young adult women with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2015; 28:457–461. doi: 10.1016/j.jpag.2015.01.002.
    1. Wang QY, Song Y, Huang W, Xiao L, Wang QS, Feng GM. Comparison of drospirenone- with cyproterone acetate-containing oral contraceptives, combined with metformin and lifestyle modifications in women with polycystic ovary syndrome and metabolic disorders: a prospective randomized control trial. Chin Med J (Engl) 2016; 129:883–890. doi: 10.4103/0366-6999.179783.
    1. Legro RS, Dodson WC, Kris-Etherton PM, Kunselman AR, Stetter CM, Williams NI, et al. . Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome. J Clin Endocrinol Metab 2015; 100:4048–4058. doi: 10.1210/jc.2015-2778.
    1. Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: etiology, treatment, and genetics. Metabolism 2019; 92:108–120. doi: 10.1016/j.metabol.2018.11.002.
    1. Dumitrescu R, Mehedintu C, Briceag I, Purcărea VL, Hudita D. Metformin-clinical pharmacology in PCOs. J Med Life 2015; 8:187–192.
    1. Sfairopoulos D, Liatis S, Tigas S, Liberopoulos E. Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones (Athens) 2018; 17:333–350. doi: 10.1007/s42000-018-0038-0.
    1. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2017; 19:524–536. doi: 10.1111/dom.12849.
    1. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344:d7771.doi: 10.1136/bmj.d7771.
    1. Sever MJ, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol 2014; 170:451–459. doi: 10.1530/EJE-13-0797.
    1. Frøssing S, Nylander M, Chabanova E, Frystyk J, Holst JJ, Kistorp C, et al. . Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial. Diabetes Obes Metab 2018; 20:215–218. doi: 10.1111/dom.13053.
    1. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93:2670–2678. doi: 10.1210/jc.2008-0115.
    1. Grossman SS. Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes. Adv Ther 2014; 31:247–263. doi: 10.1007/s12325-014-0101-4.
    1. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412–419. doi: 10.1007/bf00280883.
    1. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. . Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85:2402–2410. doi: 10.1210/jcem.85.7.6661.
    1. Seltzer HS, Allen EW, Herron AL, Jr, Brennan MT. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 1967; 46:323–335. doi: 10.1172/jci105534.
    1. Wysham CH, Rosenstock J, Vetter ML, Dong F, Öhman P, Iqbal N. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. Diabetes Obes Metab 2018; 20:165–172. doi: 10.1111/dom.13056.
    1. Zheng S, Zhang Y, Long T, Lu J, Liu X, Yan J, et al. . Short term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight/obese PCOS women. Obes Med 2017; 7:15–20. doi: 10.1016/j.obmed.2017.06.003.
    1. Liu X, Zhang Y, Zheng SY, Lin R, Xie YJ, Chen H, et al. . Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol (Oxf) 2017; 87:767–774. doi: 10.1111/cen.13454.
    1. Mhao NS, Al-Hilli AS, Hadi NR, Jamil DA, Al-Aubaidy HA. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes Metab Syndr 2016; 10:S95–S98. doi: 10.1016/j.dsx.2015.10.001.
    1. Glintborg D, Mumm H, Holst JJ, Andersen M. Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome. Endocr Connect 2017; 6:267–277. doi: 10.1530/ec-17-0034.
    1. Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, et al. . Exenatide plus metformin compared with metformin alone on β-cell function in patients with type 2 diabetes. Diabet Med 2012; 29:1515–1523. doi: 10.1111/j.1464-5491.2012.03699.x.
    1. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008; 294:E15–E26. doi: 10.1152/ajpendo.00645.2007.
    1. Su N, Li Y, Xu T, Li L, Kwong JS, Du H, et al. . Exenatide in obese or overweight patients without diabetes: a systematic review and meta-analyses of randomized controlled trials. Int J Cardiol 2016; 219:293–300. doi: 10.1016/j.ijcard.2016.06.028.
    1. Prelević GM, Würzburger MI, Trpković D, Balint-Perić L. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome. Gynecol Endocrinol 1990; 4:157–168. doi: 10.3109/09513599009009803.
    1. Villaseca P, Hormaza P, Cárdenas I, Oestreicher E, Arteaga E. Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes. Eur J Contracept Reprod Health Care 2004; 9:155–165. doi: 10.1080/13625180400007751.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera